Inhibition of influenza virus internalization by (−)-epigallocatechin-3-gallate
•EGCG inhibits the entry of influenza A and B viruses into cells with EC50 values between 5.7 and 17.3μM.•EGCG has no inhibitory effects on the viral HA and polymerase activities.•EGCG marginally inhibits the NA activity derived from influenza virus as well as from nonviral C. perfringens.•Upon EGCG...
Gespeichert in:
Veröffentlicht in: | Antiviral research 2013-11, Vol.100 (2), p.460-472 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 472 |
---|---|
container_issue | 2 |
container_start_page | 460 |
container_title | Antiviral research |
container_volume | 100 |
creator | Kim, Meehyein Kim, So-Yeon Lee, Hye Won Shin, Jin Soo Kim, Pilho Jung, Young-Sik Jeong, Hyeong-Seop Hyun, Jae-Kyung Lee, Chong-Kyo |
description | •EGCG inhibits the entry of influenza A and B viruses into cells with EC50 values between 5.7 and 17.3μM.•EGCG has no inhibitory effects on the viral HA and polymerase activities.•EGCG marginally inhibits the NA activity derived from influenza virus as well as from nonviral C. perfringens.•Upon EGCG treatment, influenza viral particles became resistant to NA and tightly fixed on the surface of cells.•EGCG damages influenza virus particle integrity, rendering viral membranes permeable and resulting in particle shrinkage.
(−)-Epigallocatechin-3-gallate (EGCG), one of the major flavonoid components of green tea, is known to have a broad antiviral activity against several enveloped viruses, including the influenza virus. However, its mode of action and the mechanism that allows it to target influenza virus molecules have not been fully elucidated. Thus, this study investigated the molecular mechanism by which EGCG suppresses influenza virus infections. EGCG was found to block an early step in the influenza viral life cycle, but it did not affect viral adsorption to target cells or viral RNA replication. However, EGCG inhibited hemifusion events between virus particles and the cellular membrane by reducing the viral membrane integrity, thereby resulting in the loss of the cell penetration capacity of the influenza virus. EGCG also marginally suppressed the viral and nonviral neuraminidase (NA) activity in an enzyme-based assay system. In conclusion, it is suggested that the anti-influenza viral efficacy of EGCG is attributable to damage to the physical properties of the viral envelope and partial inhibition of the NA surface glycoprotein. These results may facilitate future investigations of the antiviral activity of EGCG against other enveloped viruses as well as influenza virus. |
doi_str_mv | 10.1016/j.antiviral.2013.08.002 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1676350062</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0166354213002106</els_id><sourcerecordid>1449279494</sourcerecordid><originalsourceid>FETCH-LOGICAL-c500t-94015cdee7e15ec9a89683a2ad8e31d7b55172ec95a800220def3bb8481fb3853</originalsourceid><addsrcrecordid>eNqFkMFO3DAQhi1UBMu2r9DupRIcko7tOLaPCBWKtBJComfLcSbFq6yztRMkeALOfUSeBG93S4-cRr_mm5l_fkK-UCgp0PrbqrRh9A8-2r5kQHkJqgRgB2RGlWSFBl1_ILNM1gUXFTsmJymtAKCWWh2RY8a1qKhmM3J7He5940c_hMXQLXzo-gnDk13k3VPKesQYbO-f7F-keVycvjz_OStw43_Zvh-cHdHd-1DwYquz-kgOO9sn_LSvc_Lz8vvdxY9ieXN1fXG-LJwAGAtdARWuRZRIBTptla4Vt8y2CjltZSMElSw3hFX5MwYtdrxpVKVo13Al-Jyc7vZu4vB7wjSatU8Os4eAw5QMrWXN86mavY9WlWZSV7rKqNyhLg4pRezMJvq1jY-GgtlGb1bmLXqzjd6AMtlgnvy8PzI1a2zf5v5lnYGve8AmZ_su2uB8-s9JLTiAztz5jsOc3oPHaJLzGBy2PqIbTTv4d828Asi9pu4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1449279494</pqid></control><display><type>article</type><title>Inhibition of influenza virus internalization by (−)-epigallocatechin-3-gallate</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Kim, Meehyein ; Kim, So-Yeon ; Lee, Hye Won ; Shin, Jin Soo ; Kim, Pilho ; Jung, Young-Sik ; Jeong, Hyeong-Seop ; Hyun, Jae-Kyung ; Lee, Chong-Kyo</creator><creatorcontrib>Kim, Meehyein ; Kim, So-Yeon ; Lee, Hye Won ; Shin, Jin Soo ; Kim, Pilho ; Jung, Young-Sik ; Jeong, Hyeong-Seop ; Hyun, Jae-Kyung ; Lee, Chong-Kyo</creatorcontrib><description>•EGCG inhibits the entry of influenza A and B viruses into cells with EC50 values between 5.7 and 17.3μM.•EGCG has no inhibitory effects on the viral HA and polymerase activities.•EGCG marginally inhibits the NA activity derived from influenza virus as well as from nonviral C. perfringens.•Upon EGCG treatment, influenza viral particles became resistant to NA and tightly fixed on the surface of cells.•EGCG damages influenza virus particle integrity, rendering viral membranes permeable and resulting in particle shrinkage.
(−)-Epigallocatechin-3-gallate (EGCG), one of the major flavonoid components of green tea, is known to have a broad antiviral activity against several enveloped viruses, including the influenza virus. However, its mode of action and the mechanism that allows it to target influenza virus molecules have not been fully elucidated. Thus, this study investigated the molecular mechanism by which EGCG suppresses influenza virus infections. EGCG was found to block an early step in the influenza viral life cycle, but it did not affect viral adsorption to target cells or viral RNA replication. However, EGCG inhibited hemifusion events between virus particles and the cellular membrane by reducing the viral membrane integrity, thereby resulting in the loss of the cell penetration capacity of the influenza virus. EGCG also marginally suppressed the viral and nonviral neuraminidase (NA) activity in an enzyme-based assay system. In conclusion, it is suggested that the anti-influenza viral efficacy of EGCG is attributable to damage to the physical properties of the viral envelope and partial inhibition of the NA surface glycoprotein. These results may facilitate future investigations of the antiviral activity of EGCG against other enveloped viruses as well as influenza virus.</description><identifier>ISSN: 0166-3542</identifier><identifier>EISSN: 1872-9096</identifier><identifier>DOI: 10.1016/j.antiviral.2013.08.002</identifier><identifier>PMID: 23954192</identifier><identifier>CODEN: ARSRDR</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>(−)-Epigallocatechin-3-gallate ; Animals ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral activity ; Antiviral agents ; Antiviral Agents - pharmacology ; Biological and medical sciences ; Catechin - analogs & derivatives ; Catechin - pharmacology ; Cell Line ; Enzyme Inhibitors - pharmacology ; Humans ; Influenza virus ; Medical sciences ; Membrane damage ; Neuraminidase - antagonists & inhibitors ; Orthomyxoviridae - drug effects ; Orthomyxoviridae - physiology ; Pharmacology. Drug treatments ; Viral entry ; Viral Proteins - antagonists & inhibitors ; Virus Internalization - drug effects</subject><ispartof>Antiviral research, 2013-11, Vol.100 (2), p.460-472</ispartof><rights>2013 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2013 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c500t-94015cdee7e15ec9a89683a2ad8e31d7b55172ec95a800220def3bb8481fb3853</citedby><cites>FETCH-LOGICAL-c500t-94015cdee7e15ec9a89683a2ad8e31d7b55172ec95a800220def3bb8481fb3853</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0166354213002106$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27953009$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23954192$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Meehyein</creatorcontrib><creatorcontrib>Kim, So-Yeon</creatorcontrib><creatorcontrib>Lee, Hye Won</creatorcontrib><creatorcontrib>Shin, Jin Soo</creatorcontrib><creatorcontrib>Kim, Pilho</creatorcontrib><creatorcontrib>Jung, Young-Sik</creatorcontrib><creatorcontrib>Jeong, Hyeong-Seop</creatorcontrib><creatorcontrib>Hyun, Jae-Kyung</creatorcontrib><creatorcontrib>Lee, Chong-Kyo</creatorcontrib><title>Inhibition of influenza virus internalization by (−)-epigallocatechin-3-gallate</title><title>Antiviral research</title><addtitle>Antiviral Res</addtitle><description>•EGCG inhibits the entry of influenza A and B viruses into cells with EC50 values between 5.7 and 17.3μM.•EGCG has no inhibitory effects on the viral HA and polymerase activities.•EGCG marginally inhibits the NA activity derived from influenza virus as well as from nonviral C. perfringens.•Upon EGCG treatment, influenza viral particles became resistant to NA and tightly fixed on the surface of cells.•EGCG damages influenza virus particle integrity, rendering viral membranes permeable and resulting in particle shrinkage.
(−)-Epigallocatechin-3-gallate (EGCG), one of the major flavonoid components of green tea, is known to have a broad antiviral activity against several enveloped viruses, including the influenza virus. However, its mode of action and the mechanism that allows it to target influenza virus molecules have not been fully elucidated. Thus, this study investigated the molecular mechanism by which EGCG suppresses influenza virus infections. EGCG was found to block an early step in the influenza viral life cycle, but it did not affect viral adsorption to target cells or viral RNA replication. However, EGCG inhibited hemifusion events between virus particles and the cellular membrane by reducing the viral membrane integrity, thereby resulting in the loss of the cell penetration capacity of the influenza virus. EGCG also marginally suppressed the viral and nonviral neuraminidase (NA) activity in an enzyme-based assay system. In conclusion, it is suggested that the anti-influenza viral efficacy of EGCG is attributable to damage to the physical properties of the viral envelope and partial inhibition of the NA surface glycoprotein. These results may facilitate future investigations of the antiviral activity of EGCG against other enveloped viruses as well as influenza virus.</description><subject>(−)-Epigallocatechin-3-gallate</subject><subject>Animals</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral activity</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Catechin - analogs & derivatives</subject><subject>Catechin - pharmacology</subject><subject>Cell Line</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Humans</subject><subject>Influenza virus</subject><subject>Medical sciences</subject><subject>Membrane damage</subject><subject>Neuraminidase - antagonists & inhibitors</subject><subject>Orthomyxoviridae - drug effects</subject><subject>Orthomyxoviridae - physiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Viral entry</subject><subject>Viral Proteins - antagonists & inhibitors</subject><subject>Virus Internalization - drug effects</subject><issn>0166-3542</issn><issn>1872-9096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMFO3DAQhi1UBMu2r9DupRIcko7tOLaPCBWKtBJComfLcSbFq6yztRMkeALOfUSeBG93S4-cRr_mm5l_fkK-UCgp0PrbqrRh9A8-2r5kQHkJqgRgB2RGlWSFBl1_ILNM1gUXFTsmJymtAKCWWh2RY8a1qKhmM3J7He5940c_hMXQLXzo-gnDk13k3VPKesQYbO-f7F-keVycvjz_OStw43_Zvh-cHdHd-1DwYquz-kgOO9sn_LSvc_Lz8vvdxY9ieXN1fXG-LJwAGAtdARWuRZRIBTptla4Vt8y2CjltZSMElSw3hFX5MwYtdrxpVKVo13Al-Jyc7vZu4vB7wjSatU8Os4eAw5QMrWXN86mavY9WlWZSV7rKqNyhLg4pRezMJvq1jY-GgtlGb1bmLXqzjd6AMtlgnvy8PzI1a2zf5v5lnYGve8AmZ_su2uB8-s9JLTiAztz5jsOc3oPHaJLzGBy2PqIbTTv4d828Asi9pu4</recordid><startdate>20131101</startdate><enddate>20131101</enddate><creator>Kim, Meehyein</creator><creator>Kim, So-Yeon</creator><creator>Lee, Hye Won</creator><creator>Shin, Jin Soo</creator><creator>Kim, Pilho</creator><creator>Jung, Young-Sik</creator><creator>Jeong, Hyeong-Seop</creator><creator>Hyun, Jae-Kyung</creator><creator>Lee, Chong-Kyo</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T2</scope><scope>7T7</scope><scope>7U2</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>20131101</creationdate><title>Inhibition of influenza virus internalization by (−)-epigallocatechin-3-gallate</title><author>Kim, Meehyein ; Kim, So-Yeon ; Lee, Hye Won ; Shin, Jin Soo ; Kim, Pilho ; Jung, Young-Sik ; Jeong, Hyeong-Seop ; Hyun, Jae-Kyung ; Lee, Chong-Kyo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c500t-94015cdee7e15ec9a89683a2ad8e31d7b55172ec95a800220def3bb8481fb3853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>(−)-Epigallocatechin-3-gallate</topic><topic>Animals</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral activity</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Catechin - analogs & derivatives</topic><topic>Catechin - pharmacology</topic><topic>Cell Line</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Humans</topic><topic>Influenza virus</topic><topic>Medical sciences</topic><topic>Membrane damage</topic><topic>Neuraminidase - antagonists & inhibitors</topic><topic>Orthomyxoviridae - drug effects</topic><topic>Orthomyxoviridae - physiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Viral entry</topic><topic>Viral Proteins - antagonists & inhibitors</topic><topic>Virus Internalization - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Meehyein</creatorcontrib><creatorcontrib>Kim, So-Yeon</creatorcontrib><creatorcontrib>Lee, Hye Won</creatorcontrib><creatorcontrib>Shin, Jin Soo</creatorcontrib><creatorcontrib>Kim, Pilho</creatorcontrib><creatorcontrib>Jung, Young-Sik</creatorcontrib><creatorcontrib>Jeong, Hyeong-Seop</creatorcontrib><creatorcontrib>Hyun, Jae-Kyung</creatorcontrib><creatorcontrib>Lee, Chong-Kyo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Safety Science and Risk</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Antiviral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Meehyein</au><au>Kim, So-Yeon</au><au>Lee, Hye Won</au><au>Shin, Jin Soo</au><au>Kim, Pilho</au><au>Jung, Young-Sik</au><au>Jeong, Hyeong-Seop</au><au>Hyun, Jae-Kyung</au><au>Lee, Chong-Kyo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of influenza virus internalization by (−)-epigallocatechin-3-gallate</atitle><jtitle>Antiviral research</jtitle><addtitle>Antiviral Res</addtitle><date>2013-11-01</date><risdate>2013</risdate><volume>100</volume><issue>2</issue><spage>460</spage><epage>472</epage><pages>460-472</pages><issn>0166-3542</issn><eissn>1872-9096</eissn><coden>ARSRDR</coden><abstract>•EGCG inhibits the entry of influenza A and B viruses into cells with EC50 values between 5.7 and 17.3μM.•EGCG has no inhibitory effects on the viral HA and polymerase activities.•EGCG marginally inhibits the NA activity derived from influenza virus as well as from nonviral C. perfringens.•Upon EGCG treatment, influenza viral particles became resistant to NA and tightly fixed on the surface of cells.•EGCG damages influenza virus particle integrity, rendering viral membranes permeable and resulting in particle shrinkage.
(−)-Epigallocatechin-3-gallate (EGCG), one of the major flavonoid components of green tea, is known to have a broad antiviral activity against several enveloped viruses, including the influenza virus. However, its mode of action and the mechanism that allows it to target influenza virus molecules have not been fully elucidated. Thus, this study investigated the molecular mechanism by which EGCG suppresses influenza virus infections. EGCG was found to block an early step in the influenza viral life cycle, but it did not affect viral adsorption to target cells or viral RNA replication. However, EGCG inhibited hemifusion events between virus particles and the cellular membrane by reducing the viral membrane integrity, thereby resulting in the loss of the cell penetration capacity of the influenza virus. EGCG also marginally suppressed the viral and nonviral neuraminidase (NA) activity in an enzyme-based assay system. In conclusion, it is suggested that the anti-influenza viral efficacy of EGCG is attributable to damage to the physical properties of the viral envelope and partial inhibition of the NA surface glycoprotein. These results may facilitate future investigations of the antiviral activity of EGCG against other enveloped viruses as well as influenza virus.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>23954192</pmid><doi>10.1016/j.antiviral.2013.08.002</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0166-3542 |
ispartof | Antiviral research, 2013-11, Vol.100 (2), p.460-472 |
issn | 0166-3542 1872-9096 |
language | eng |
recordid | cdi_proquest_miscellaneous_1676350062 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | (−)-Epigallocatechin-3-gallate Animals Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral activity Antiviral agents Antiviral Agents - pharmacology Biological and medical sciences Catechin - analogs & derivatives Catechin - pharmacology Cell Line Enzyme Inhibitors - pharmacology Humans Influenza virus Medical sciences Membrane damage Neuraminidase - antagonists & inhibitors Orthomyxoviridae - drug effects Orthomyxoviridae - physiology Pharmacology. Drug treatments Viral entry Viral Proteins - antagonists & inhibitors Virus Internalization - drug effects |
title | Inhibition of influenza virus internalization by (−)-epigallocatechin-3-gallate |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T21%3A44%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20influenza%20virus%20internalization%20by%20(%E2%88%92)-epigallocatechin-3-gallate&rft.jtitle=Antiviral%20research&rft.au=Kim,%20Meehyein&rft.date=2013-11-01&rft.volume=100&rft.issue=2&rft.spage=460&rft.epage=472&rft.pages=460-472&rft.issn=0166-3542&rft.eissn=1872-9096&rft.coden=ARSRDR&rft_id=info:doi/10.1016/j.antiviral.2013.08.002&rft_dat=%3Cproquest_cross%3E1449279494%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1449279494&rft_id=info:pmid/23954192&rft_els_id=S0166354213002106&rfr_iscdi=true |